Biotechnology company, Moderna Therapeutics, has entered a strategic R&D collaboration with ElevateBio’s wholly-owned gene-editing subsidiary, Life Edit Therapeutics, to identify and develop novel gene-editing-based therapeutics for genetic and other diseases.
Life Edit will be eligible to receive an upfront payment together with milestone and royalty payments from Moderna. The detailed terms and financial details of the partnership were not disclosed.
The partnership will leverage Life Edit’s proprietary gene-editing technologies, such as base editing and Moderna’s messenger ribonucleic acid (mRNA) platform, to develop novel in-vivo treatments for a number of undisclosed therapeutic targets. Moderna will fund the programs and upon identifying suitable targets, it will take responsibility for the development, manufacturing, and commercialization.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.